Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapy

Angelina Tjokrowidjaja, Chee K Lee, Michael Friedlander, Val Gebski, Laurence Gladieff, Jonathan Ledermann, Richard Penson, Amit Oza, Jacob Korach, Tomasz Huzarski, Luis Manso, Carmela Pisano, Rebecca Asher, Sarah J Lord, Se Ik Kim, Jung-Yun Lee, Nicoletta Colombo, Tjoung-Won Park-Simon, Keiichi Fujiwara, Gabe SonkeIgnace Vergote, Jae-Weon Kim, Eric Pujade-Lauraine

Research output: Contribution to journalArticlepeer-review

Fingerprint Dive into the research topics of 'Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapy'. Together they form a unique fingerprint.

Medicine & Life Sciences